| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2007PNAS..104.8444Z |
| P356 | DOI | 10.1073/PNAS.0702496104 |
| P932 | PMC publication ID | 1895969 |
| P698 | PubMed publication ID | 17488826 |
| P5875 | ResearchGate publication ID | 6342290 |
| P50 | author | Thomas Waldmann | Q21042387 |
| P2093 | author name string | Zhuo Zhang | |
| Martin W Brechbiel | |||
| Meili Zhang | |||
| Zhengsheng Yao | |||
| Hiral Patel | |||
| John E Janik | |||
| Carolyn K Goldman | |||
| Kayhan Garmestani | |||
| Paul S Plascjak | |||
| Vladimir S Talanov | |||
| P2860 | cites work | Immunotherapy: past, present and future | Q22251059 |
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family | Q28208696 | ||
| Antibody-targeted radiation cancer therapy | Q28264580 | ||
| Anti-CD30 antibody-based therapy | Q34086171 | ||
| Tumor therapy with targeted atomic nanogenerators | Q34102138 | ||
| The promise of targeted {alpha}-particle therapy. | Q34384845 | ||
| Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts | Q34762427 | ||
| A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1) | Q35788227 | ||
| CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule | Q35796182 | ||
| ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters | Q35808435 | ||
| Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors | Q35848928 | ||
| Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25 | Q35849893 | ||
| Radioimmunotherapy with alpha-particle emitting radionuclides. | Q36004564 | ||
| Lymphomatoid papulosis, Ki-1+ lymphoma, and primary cutaneous Hodgkin's disease | Q36434938 | ||
| The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia | Q40243247 | ||
| CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications | Q40415907 | ||
| Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody | Q40512788 | ||
| CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. | Q40810972 | ||
| Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient. | Q41206007 | ||
| Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac | Q43752162 | ||
| CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | Q43864036 | ||
| Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. | Q43893152 | ||
| Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. | Q44031707 | ||
| Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin. | Q44183113 | ||
| Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. | Q44417050 | ||
| Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. | Q44656909 | ||
| Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. | Q45214278 | ||
| Signal transduction in anaplastic large cell lymphoma cells (ALCL) mediated by the tumor necrosis factor receptor CD30. | Q50488809 | ||
| 131I-tositumomab therapy as initial treatment for follicular lymphoma. | Q54682444 | ||
| Indications for autologous bone marrow transplantation in Hodgkin's disease | Q68002679 | ||
| Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas | Q68243663 | ||
| Radioimmunotherapy with alpha-particle-emitting immunoconjugates | Q69918183 | ||
| Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin | Q70290393 | ||
| Expression of CD30 and nerve growth factor-receptor in neoplastic and reactive vascular lesions: an immunohistochemical study | Q70496942 | ||
| In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts | Q71805061 | ||
| Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells | Q73281237 | ||
| Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? | Q73358716 | ||
| Expression of the CD30 antigen in non-lymphoid tissues and cells | Q73572584 | ||
| The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma | Q73708711 | ||
| Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience | Q74171684 | ||
| Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets | Q74190642 | ||
| The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease | Q74409841 | ||
| Targeted alpha particle immunotherapy for myeloid leukemia | Q74541298 | ||
| Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies | Q74561495 | ||
| CD30 expression is common in mediastinal large B-cell lymphoma | Q78105218 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| antibody | Q79460 | ||
| murine model | Q122890741 | ||
| P304 | page(s) | 8444-8 | |
| P577 | publication date | 2007-05-15 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1 | |
| P478 | volume | 104 |
| Q34542109 | A novel role for IL-22R1 as a driver of inflammation |
| Q37743339 | Anti-CD30 Antibodies for Hodgkin lymphoma. |
| Q33640550 | Astatine Radiopharmaceuticals: Prospects and Problems |
| Q38138482 | CD30 as a therapeutic target for lymphoma |
| Q36777329 | Epidermal Growth Factor Receptor–Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using 90Y-Labeled Fully Human Antibody Panitumumab |
| Q52656403 | Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models. |
| Q36534262 | Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy |
| Q34419562 | Radioimmunotherapy with α-particle-emitting radionuclides |
| Q38052082 | Targeting CD30 in anaplastic large cell lymphoma |
| Q33944427 | Targeting of a developmentally regulated epitope of CD43 for the treatment of acute leukemia |
| Q47102763 | Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions |
| Q45764153 | Utilizing CD30 expression as a rational target for therapy of lymphoma |
Search more.